CXCL10 and neoplasm: noted that the pretreatment serum concentrations of CXCL10 and CXCL11 in lung cancer patients receiving anti‐PD‐1 antibodies were significantly correlated with clinical outcomes, and identified tumor‐derived CXCL10/11 as a potential circulating biomarker for monitoring drug treatment sensitivity.